John Tlumacki/Boston Globe via AP

STAT+ | Lindsay Clancy case exposes dangers of fragmented U.S. health system, experts say

Before the deaths of her children, Clancy got 30 prescriptions from five clinicians and two hospitals. Lack of coordination cited as key factor in tragic outcome.

By Tara Bannow

STAT+ | After failure of Angelman syndrome drug, experts see hope in other experimental therapies

Like Ultragenyx, Ionis and Oak Hill Bio are developing their own antisense treatments for Angelman syndrome.

By Jason Mast

STAT+ | Top Boston hospitals clash over Medicare Advantage network after split

Mass General Brigham's Medicare Advantage plan is dropping coverage of Dana-Farber, a top cancer center.

By Marin Wolf — Boston Globe

Shelby Lum/AP

STAT+ | Recipients of gene-edited pig kidneys successfully receive human organs

The pair of cases mark a milestone for the biotech company eGenesis in its wider effort to advance xenografts.

By Eric Boodman

Opinion: The FDA removed the red tape around one of the best drugs for children with schizophrenia. But the fear remains

For children with schizophrenia, clozapine can be close to miraculous. Doctors are too reluctant to use it, writes expert.

By Nitin Gogtay

STAT+ | Ionis wins FDA approval for first drug for Alexander disease, a rare and deadly neurological disorder

Ionis Pharmaceuticals receives FDA approval for Zanvastro, the first disease-modifying therapy for rare and fatal neurological Alexander disease.

By Jonathan Wosen